Stereotaxis (NYSE:STXS), a pioneer in innovative robotic technologies for the treatment of cardiac arrhythmias, announced on April 6, 2026, that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Synchrony™ interventional lab display system.
The commercial launch of Synchrony marks a strategic expansion for Stereotaxis, moving beyond its core robotic navigation platforms into the broader catheterization lab (cath lab) infrastructure market.
The system features a massive 55-inch 4K medical-grade display designed specifically for high-stakes interventional procedures.
Key technical advantages include ultra-low latency video processing—critical for real-time surgical guidance—and built-in "obsolescence protection" to ensure compatibility with evolving imaging hardware.
Central to the Synchrony value proposition is the integrated SynX™ platform.
This cloud-based software enables HIPAA and GDPR-compliant remote collaboration, allowing physicians to share live procedural video and data with off-site experts or proctors in real time.
The company noted that this connectivity is a foundational step toward future AI-enabled applications, which could eventually provide automated procedural insights directly on the Synchrony screen.
Financially, Stereotaxis reiterated its previous guidance, projecting over $3 million in 2026 revenue derived specifically from Synchrony placements.